Livingston, NJ, United States of America

Carmen S Alvarez

USPTO Granted Patents = 19 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.0

ph-index = 10

Forward Citations = 212(Granted Patents)

Location History:

Roselle Park, NJ (US) (1999 - 2008)
Livingston, NJ (US) (2006 - 2014)

Company Filing History:

Pharmacopeia Drug Discovery, Inc.

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 1999-2014

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8673924 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2014-03-18),

2. 7807683 - N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors (2010-10-05),

3. 7776865 - Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors (2010-08-17),

4. 7514442 - Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors (2009-04-07),

5. 7342016 - Farnesyl protein transferase inhibitors as antitumor agents (2008-03-11),

6. 7161003 - Pyrazolopyrimidines as cyclin dependent kinase inhibitors (2007-01-09),

7. 7119200 - Pyrazolopyrimidines as cyclin dependent kinase inhibitors (2006-10-10),

8. 7067661 - Pyrazolopyrimidines as cyclin dependent kinase inhibitors (2006-06-27),

9. 6740661 - Farnesyl protein transferase inhibitors (2004-05-25),

10. 6440974 - Compounds useful for inhibition of farnesyl protein transferase (2002-08-27),

11. 6410541 - Compounds useful for inhibition of farnesyl protein transferase (2002-06-25),

12. 6387905 - Compounds useful for inhibition of farnesyl protein transferase (2002-05-14),

13. 6372747 - Farnesyl protein transferase inhibitors (2002-04-16),

14. 6228865 - Compounds useful for inhibition of farnesyl protein transferase (2001-05-08),

15. 6228856 - Compounds useful for inhibition of farnesyl protein transferase (2001-05-08),

Title: Carmen S. Alvarez: Innovator in Cyclin Dependent Kinase Inhibition

Introduction

Carmen S. Alvarez, based in Livingston, NJ, is a notable innovator with an impressive portfolio of 19 patents. His work primarily focuses on the development of novel compounds aimed at inhibiting cyclin dependent kinases (CDKs), which play critical roles in cell cycle regulation and cancer progression.

Latest Patents

Among his latest contributions, Alvarez has developed substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors. This invention outlines methods for inhibiting one or more CDKs in patients by administering effective amounts of pyrazolo[1,5-a]pyrimidine compounds. Additionally, he has introduced a class of N-heteroaryl pyrazolopyrimidines particularly designed as inhibitors for these kinases. Both patents detail therapeutic approaches that could lead to innovative treatments for diseases associated with CDK activities.

Career Highlights

Throughout his career, Alvarez has collaborated with prominent pharmaceutical companies such as Schering Corporation and Pharmacopeia Drug Discovery, Inc. His commitment to research and innovation has enabled him to make significant advancements in the field of drug discovery and development.

Collaborations

In his professional journey, Alvarez has worked alongside distinguished colleagues like Ronald J. Doll and Tarik Lalwani. These collaborations have fostered a robust exchange of ideas and expertise, enhancing the impact of their collective work on the pharmaceutical landscape.

Conclusion

Carmen S. Alvarez's innovations in the area of cyclin dependent kinase inhibitors represent a significant step forward in therapeutic possibilities for diseases influenced by these vital enzymes. His ongoing contributions reflect a dedication to advancing medical science and improving patient outcomes through targeted pharmaceutical strategies.

This text is generated by artificial intelligence and may not be accurate.